Citius Oncology
CTOR
22 hedge funds and large institutions have $56.8M invested in Citius Oncology in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
5% more capital invested
Capital invested by funds: $54.1M → $56.8M (+$2.74M)
8% less funds holding
Funds holding: 24 → 22 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2.93M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$3.66M |
| 2 |
KL
KIM LLC
Wichita,
Kansas
|
+$2.09M |
| 3 |
MSU
Mizuho Securities USA
New York
|
+$1.42M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$772K |
| 5 |
VF
Virtu Financial
New York
|
+$335K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$3.64M |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$2.62M |
| 3 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$200K |
| 4 |
SG
StoneX Group
New York
|
-$188K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$131K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSA
26
Schonfeld Strategic Advisors
New York
| – | -$131K | -12,600 | Closed |
|
27
UBS Group
Zurich,
Switzerland
| – | -$15.6K | -1,504 | Closed |
|
CTOR Hedge Fund Activity: Q2 2023 in Review
22 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Citius Oncology (CTOR) for Q2 2023, worth a combined $56.8M — up 5.1% from $54.1M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CTOR and 3 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Rivernorth Capital Management, opening a new position worth an estimated $3.66M. The largest seller was Weiss Asset Management, exiting entirely with an estimated $3.64M sold.
- 22 institutional investors held Citius Oncology (CTOR) as of Q2 2023, down from 24 in Q1 2023.
- Funds reported $56.8M of Citius Oncology stock for Q2 2023, up 5.1% quarter-over-quarter.
- 3 funds opened new Citius Oncology positions in Q2 2023 and 5 closed out, a net change of -2 holders.
- The largest Citius Oncology buyer in Q2 2023 was Rivernorth Capital Management, an estimated $3.66M added.
- The largest Citius Oncology seller in Q2 2023 was Weiss Asset Management, an estimated $3.64M sold.
Based on aggregated 13F filings for Q2 2023.